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Background: Bladder pain syndrome (BPS), a condition with no gold standard diagnosis, comprises of a cluster of
signs and symptoms. Bladder filling pain and bladder wall tenderness are two basic clinical features, present in a
high number of sufferers. This study will validate the performance of these simple tests for BPS in women with
chronic pelvic pain (CPP).
Methods/design: We will conduct a prospective test validation study amongst women with unexplained CPP
presenting to gynaecology outpatient clinics. Two index tests will be performed: patient reported bladder filling
pain and bladder wall tenderness on internal pelvic bimanual examination. A final diagnosis of BPS will be made by
expert consensus panel. We will assess the rates of index tests in women with CPP; evaluate the correlation
between index tests and Pelvic Pain Urgency/ Frequency (PUF) questionnaire results; and determine index test
sensitivity and specificity using a range of analytical methods. Assuming a 50% prevalence of BPS and an 80%
power approximately 152 subjects will be required exclude sensitivity of < 55% at 70% sensitivity.
Discussion: The results of this test validation study will be used to identify whether a certain combination of signs
and symptoms can accurately diagnose BPS.
Trial registration: ISRCTN13028601
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Bladder pain syndrome (BPS), formerly known as inter-
stitial cystitis and painful bladder syndrome, is a cause of
chronic pelvic pain (CPP) and is defined as CPP, bladder
pressure or discomfort along with at least one other
urinary symptom in the absence of any identifiable path-
ology or infection [1,2].
The reported prevalence of BPS is between 5 and 16
per 100,000 of the population with 61% of women pre-
senting with CPP being diagnosed with BPS [3-5]. The
condition has a large impact on sexual function and
quality of life [6]. It has an unknown aetiology and impre-
cise characterisation, which makes it difficult to accurately* Correspondence: s.a.tirlapur@qmul.ac.uk
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stated.diagnose clinically [7,8]. The diagnosis of BPS can be
made by symptoms alone and further classified by cyst-
oscopy findings and biopsy results, after exclusion of
other confusable diseases like urinary tract infection or
overactive bladder [2]. Symptoms include urinary fre-
quency, urgency, nocturia and incomplete voiding [9].
Validated questionnaires may be used to help diagnose
patients. The two commonly used are the O’Leary-Sant
Interstitial Cystitis Symptom Index/Problem Index and
the Pelvic Pain Urgency/ Frequency (PUF) question-
naire [10,11]. Neither questionnaire is considered a reli-
able predictor of disease or disease severity [11,12].
There is no gold standard test for BPS, which makes for
difficulty in choice of study design for a diagnostic eva-
luation study (Figure 1).
The most commonly reported symptoms are bladder/
pelvic pain, urgency, frequency and nocturia but this symp-
tom cluster is present in several other urinary conditionsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Figure 1 Flow diagram showing the possible options for researchers when there is no clear reference standard in diagnostic accuracy
studies [13].
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http://www.reproductive-health-journal.com/content/10/1/61and is not discriminating of BPS [14]. In practice, the symp-
tom of bladder filling pain and the sign of bladder wall ten-
derness on vaginal examination have been shown to be
present in a high number of patients with BPS, but these
have not been incorporated into existing tools [15,16]. This
study will validate the use of these simple tests for BPS in
women with CPP.Methods/design
The BRaVADO study will be conducted prospectively and
its protocol is reported in accordance with the SPIRIT
guidelines [17]. This will be a sub-study of the MEDAL
trial (MRI to Establish Diagnosis Against Laparoscopy),
which is a multicentre diagnostic test accuracy study car-
ried out in United Kingdom to investigate women with
unexplained chronic pelvic pain.
Trial registration: Ethics and research and develop-
ment approvals for this study are covered through the
multicentre research ethics committee (REC no: 11/EM/
0281). The study is sponsored by Queen Mary, Univer-
sity of London (Ref no: 007936 QM). Clinical trial regis-
tration no: ISRCTN13028601.Objectives:
1. To determine the rates of the symptom of bladder
filling pain and the sign of bladder wall tenderness
in women with CPP.
2. To assess the correlation between bladder filling
pain, bladder wall tenderness, and the PUF
questionnaire (and several component questions
within it) in the diagnosis of BPS in CPP.
3. To determine the prevalence of BPS in CPP,
using consensus panel to establish reference
standard diagnosis.
4. To estimate the accuracy with which a certain
combination of signs and symptoms (index tests)
can identify the diagnosis of BPS in CPP.Design
Prospective test validation study with consensus panel to
establish reference diagnosis.Setting
Gynaecology outpatient clinics in the United Kingdom.
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Women presenting to secondary care with unexplained
CPP. The inclusion criteria are women aged 16 or older
who are referred to secondary care with unexplained CPP
and have the ability to understand adequate English to
give informed consent. Exclusion criteria are pregnancy, a
previous hysterectomy, a proven urinary tract infection on
urine dipstick and a previous diagnosis of BPS.
Index tests:
1. Bladder filling pain will be assessed through a
patient questionnaire (Figure 2). There is also
assessment of pain when the bladder is full to
discriminate the two.
2. Bladder base tenderness will be assessed by
specialists in gynaecology as part of a routine vaginal
examination. This is the sensation of pain when the
bladder wall is palpated, rather than a sensation of
discomfort.
Reference tests
There is no gold standard test for diagnosis. We will have
an expert consensus panel in the study. The panel will be
made of 3 national specialists in urogynaecology. The diag-
nosis determined by the panel will be a symptom-based
diagnosis of BPS through patient self-reporting symptoms
captured in a range of validated questionnaires. Figure 3
shows the proforma to be used for the consensus panels.
Recruitment
All eligible patients will be invited to participate in the
study. They will be consented by named research staff at
all participating centres, according to the MEDAL proto-
col version 1.2. There will be consecutive recruitment of
all eligible patients to minimise selection bias (Figure 4).a.
b.
Figure 2 Index test questions. a. Bladder filling pain. b. Bladder wall tendSample size
The power estimation for such test validation studies is
not straightforward. Estimates of prevalence of BPS vary.
A recent systematic review suggested the prevalence of
BPS in women with CPP is as high as 61% [3,4]. Since the
exact prevalence in unknown, a range of sample sizes have
been calculated based on various levels of prevalence
(Table 1). There are no published estimates of sensitivity,
as defined as having a positive index test and actually hav-
ing BPS. We use a 95% confidence interval and exact test
to estimate sample sizes, excluding a sensitivity range of
less than 45% to 65% with a power of 80%. For example,
assuming a 50% prevalence of BPS and an 80% power ap-
proximately 152 subjects will be required exclude sensitiv-
ity of < 55% at 70% sensitivity.
Proposed time schedule
Table 2 shows the study timeline with recruitment com-
mencing August 2012 and study end date of September
2014 [17].
Data collection
Data will be collected on the pre-designed data collection
forms and inputted into the central database. Quality assur-
ance testing will take place with double data entry, visual
cross validation, data completeness checks and protocol ad-
herence. All patients will undergo a diagnostic laparoscopy
and cystoscopy, if deemed clinically necessary. Information
will be collected about co-existing causes of CPP. The in-
formation collected will be represented in a STARD flow
diagram (Figure 4).
Data analyses
Patient characteristics will be recorded. We will provide
descriptive statistics with ranges and standard deviations
as appropriate. Statistical analyses will compute sensitivity,
specificity and predictive values using consensus panelerness.
Figure 3 Consensus panel assessment form for symptom-based diagnosis of bladder pain syndrome.
Figure 4 Study flow chart in accordance with the STARD reporting guidelines [18].
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70% 55% 76 190 152 127
75% 60% 73 183 146 122
80% 65% 69 173 132 115
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http://www.reproductive-health-journal.com/content/10/1/61diagnosis as reference. We will consider several approaches
to test validation [13]. The flow diagram in Figure 1 shows
how we arrived at the proposed data analyses method-
ology. In the absence of a single reference standard to pro-
vide adequate diagnostic classification and the lack of
information regarding the degree of imperfection of the
reference standards, multiple tests can be used. As there is
no consensus on pre-defined rules to define the target con-
dition, we will use an expert panel diagnosis. Accuracy is
concurrent criterion validity. In order to avoid incorpor-
ation bias, we will not include the index tests as part of the
symptom based diagnosis. From the certainty scores of
diagnosis we will calculate median and confidence interval
scores, and kappa for inter-rater reliability. We will report
all estimates of test performance with confidence intervals.
We will also explore the use of latent class analysis, which
is a statistical test that allows evaluation of a new test in
the absence of a gold standard [19].Table 2 A schematic diagram showing the timeline for study
TIMEPOINT -t1 0
t1








Bladder filling pain X
Bladder wall tenderness X
ASSESSMENTS:
Validated questionnaires X X
Vaginal examination X
Diagnostic laparoscopy
Expert panel (reference diagnosis)
DATA ANALYSIS
COMPLETE REPORTData monitoring
Data monitoring will be undertaken in accordance with
guidelines for diagnostic studies [20]. Quality testing with
range checks for data values and standard operating proce-
dures will be used to maintain accurate data reporting and
monitoring. Regular data monitoring committee meetings
will be scheduled with a group of independent experts.
Discussion
The results of this test validation study will be used to
identify whether a certain combination of signs and symp-
toms can accurately predict the diagnosis of BPS. In 2011
the American Urological Association produced their guide-
lines for diagnosis and management of BPS, which are
summarised in Figure 5 [21]. Since then, cystoscopic find-
ings have been discredited as a negative cystoscopy does
not exclude BPS and cystoscopic findings do not correlate
well with disease severity or histopathology [22,23]. Forparticipation [17]
t2 t3 t4 tx





Figure 5 A summary of the American urological association guidelines [21].
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http://www.reproductive-health-journal.com/content/10/1/61this reason cystoscopy and bladder biopsy can no longer
be used as a gold standard diagnostic tool for the condi-
tion. According to the 2011 guidelines, initial treatment
with pain management, behavioural modifications, patient
education and physical therapies can be commenced after
basic assessment consisting of history, pain assessment,
physical examination and urinalysis. Cystoscopy and hydro-
distension are recommended as a fourth-line treatment for
BPS as this investigation may provide limited diagnostic
and therapeutic benefit [24]. If a cluster of signs and symp-
toms could accurately predict BPS this could be incorpo-
rated into the basic clinical assessment and would help
clinicians diagnose the condition and initiate treatments
without lengthy delays performing investigations, which are
often not discriminatory.
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